Core Knowledge in Action

The Core Knowledge in Action series at ACC.24 is guided by prominent clinicians and leaders, and focuses on important fundamentals in managing and treating heart conditions. In addition, we'll review updated clinical guidelines and best practices. Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting. Each session is interactive and includes knowledge check-ins and dedicated time for discussion. Whether you are a cardiovascular practitioner or a non-physician provider, this series will provide real-world guidance to improve the care of patients in your practice.

When Statins Are Not Enough – Non-statin Lipid Lowering Therapies (Session 801)

The session will examine non-statin pharmacologic therapies, including ezetimibe, PCSK9 inhibitors, inclisiran and bempedoic acid to lower LDL and cardiovascular risk. Learn practical knowledge on how to integrate non-statin therapies, including when and how to use them for optimal patient outcomes. The session will conclude with a knowledge check in and an interactive question and answer session with the experts.

Heart Failure With Preserved Ejection Fraction... Making to Find It, and How to Treat It (Session 802)

This insightful session will delve into HFpEF covering topics such as diagnosis, evidence-based therapies, and the nuances of medical intervention. Learn practical insights in diagnosing HFpEF, when exercise hemodynamics play a crucial role and the cath lab may not be readily available, and gain a better understanding of effective treatment strategies. Explore how to optimize outcomes by addressing comorbidities, emphasizing the importance of treating the whole patient for a comprehensive approach to HFpEF management. The session will conclude with an engaging open forum, allowing for interactive questions and answers.

Is Viability Still Viable and How Should We Assess It? (Session 803)

This session will unravel the current landscape on using viability to inform coronary revascularization, exploring the pros and cons of available imaging modalities. Kicking off with a thought-provoking debate on the relevance of viability studies prior to revascularization, hear as experts weigh the pros and cons, addressing the cost implications, limitations on revascularization, and the predictability of outcomes associated with viability studies. The session will feature case-based examples showcasing the use of viability studies, offering real-world insights into their application and experts will navigate attendees through the spectrum of imaging modalities, from Q waves to MRI, and explore the nuances of echocardiography, SPECT, PET, and cardiac MRI for viability assessment. The session will end with an interactive question and answer session where you'll have an opportunity to ask the experts your questions.

Too Many Choices? When to Use What Modality For the Assessment of Coronary Artery Disease (Session 804)

This comprehensive discussion will guide you through the options in the assessment of coronary artery disease (CAD),Z providing a detailed exploration of CT, Echo, nuclear, and MRI. Kicking off the session, experts will debate the merits of CT Angiography as the test of choice for patients with suspected CAD. Delve into the practical aspects of stress echocardiography through a case-based discussion, unraveling the intricacies of when and how to employ this valuable diagnostic tool. Explore the pros and cons of nuclear stress testing and explore the capabilities of MRI in providing a holistic understanding of coronary artery disease. The session will wrap up with an interactive question and answer session where you'll have an opportunity to ask the experts your questions.

Antiplatelet Therapy After Coronary Stenting – What You Need to Know (Session 805)

Expert faculty will navigate the complex landscape of antiplatelet therapies with a specialized focus on post-percutaneous coronary intervention (PCI) management to keep you at the forefront of this rapidly evolving field amidst the recent trial and guideline updates. Explore the key points to remember in dual antiplatelet therapy (DAPT) after PCI, gain a comprehensive understanding of P2Y12 inhibitors—clopidogrel, prasugrel, and ticagrelor—making the selection process simple and informed, and discuss the intricacies of managing patients facing impending surgery or those who have recently undergone PCI. In addition, case-based discussions will provide you with a look at real-world scenarios to guide you on how to individualize antiplatelet therapy for your patients.

American College of Cardiology

© 2023 American College of Cardiology Foundation. Visit

Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us